Home  |  About SITC  |  Contact Us

SITC 30th Anniversary Annual Meeting


The SITC 2015 Presentation Archive is supported through a generous contribution from AstraZeneca/MedImmune.

Access slide decks and video via the links in the schedule below.

PDF = PDF of slides is available

VIDEO = Presentation video is available

Program Schedule

Friday, November 6, 2015
 

7:00 – 7:45 a.m. State of SITC: Membership Business Meeting
7:45 – 7:50 a.m. Presidential Welcome
Howard L. Kaufman, MD, FACS – Rutgers Cancer Institute of New Jersey

Milestones in Immunotherapy

Non-CME Session
7:50 – 8:20 a.m. Targeting Immune Checkpoints in Cancer Therapy:  New Insights, Opportunities and Prospects for a Cure  PDF  VIDEO
James P. Allison, PhD – University of Texas MD Anderson Cancer Center
8:20 – 8:50 a.m. From Immune Surveillance to Personalized Cancer Vaccines  PDF  VIDEO
Robert Schreiber, PhD – Washington University School of Medicine
8:50 – 9:20 a.m. Therapeutic Cancer Vaccines
Cornelis J.M. Melief, MD, PhD – Leiden University Medical Center
9:20 – 9:50 a.m. Curative Potential of Cell Transfer Therapy for Cancer  PDF  VIDEO
Steven A. Rosenberg, MD, PhD – National Cancer Institute, National Institutes of Health
9:50 – 9:55 a.m. Questions and Answers
9:55 – 10:15 a.m. Break
 

New Insights into T Cell Function

1.75 AMA PRA Category 1 Credits™

Co-Chairs:
Rafi Ahmed, PhD – Emory University
Pamela S. Ohashi, PhD – Princess Margaret Cancer Centre
10:15 – 10:20 a.m. Introduction
Pamela S. Ohashi, PhD – Princess Margaret Cancer Centre
10:20 – 10:40 a.m. Building Curative Anti-tumor T cells  PDF  VIDEO
Nicholas P. Restifo, MD – National Cancer Institute
10:40 – 11 a.m. Tissue Resident Memory T Cells  PDF  VIDEO
David Masopust, PhD – University of Minnesota
11 – 11:20 a.m. T Cell Exhaustion  PDF  VIDEO
Rafi Ahmed, PhD – Emory University
11:20 – 11:40 a.m. New Insights into CD8 Function and Regulation  PDF
Pamela S. Ohashi, PhD – Princess Margaret Cancer Centre
11:40 – 11:55 p.m. Tissue Resident Memory T Cells Create Genetically Distinct Immune Microenvironment within Melanoma Metastasis
Kavita Dhodapkar, MD – Yale University
11:55 – Noon Closing Remarks
Rafi Ahmed, PhD – Emory University
 

Late Breaking Abstract Session I

Non-CME Session

Noon – 12:15 p.m. Preliminary Results from a PhaseI/II Study of Epacadostat (incb024360) in Combination with Pembrolizumab in Patients with Selected Advanced Cancers  PDF  VIDEO
Tara C. Gangadhar, MD – Abramson Cancer Center of the University of Pennsylvania
12:15 – 12:30 p.m. The PTEN Pathway in Tregs Fuctions as a Critical Driver of the Immunosuppressive Tumor Microenvironment and Tolerance to Apoptotic Cells  PDF  VIDEO
David H. Munn, MD – Georgia Regents University Cancer Center
12:30 – 12:45 p.m. Tumor Response from Durvalumab (MED14736) + Tremelimumab Treatment in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) is Observed Regardless of PD-L1 Status  PDF  VIDEO
Naiyer A. Rizvi, MD – Columbia University Medical Center
12:45 – 2 p.m. Lunch and Poster Viewing
   

Smalley Keynote

.5 AMA PRA Category 1 Credits™

2 – 2:05 p.m. Introduction
Howard L. Kaufman, MD, FACS – Rutgers Cancer Institute of New Jersey
2:05 – 2:30 p.m. Smalley Keynote Presentation  PDF  VIDEO
Tasuku Honjo, MD, PhD – Deparment of Immunology and Genomic Medicine, Graduate School of Medicine, Kyoto University
2:30 – 2:35 p.m. Question & Answer
Tasuku Honjo, MD, PhD – Department of Immunology and Genomic Medicine, Graduate School of Medicine, Kyoto University

Adoptive Immunotherapy

Developed in Collaboration with International Society for Cell Therapy (ISCT)
1.75 AMA PRA Category 1 Credits

Co-Chairs:
Malcolm K. Brenner, MD, PhD – Baylor College of Medicine
Bruce Levine, PhD – Abramson Cancer Center, University of Pennsylvania
2:35 – 2:55 p.m. Enhancing CAR T Cell Activity via the TCR
Cliona M. Rooney, PhD – Baylor College of Medicine
2:55 – 3:15 p.m. Functional Determinants of Highly Active Cell Therapy
Stephen Grupp, MD, PhD – University of Pennsylvania
3:15 – 3:35 p.m. Regulatory T Cells to Induce Tolerance in Hematopoletic Stem Cell Transplantation
Bruce R. Blazar, MD – University of Minnesota
3:35 – 3:50 p.m. Durable Complete Response in a Patient with Metastatic Melanoma Following Adoptive Transfer of Autologous T Cells Recognizing 10 Mutated Tumor Antigens  PDF  VIDEO
Todd Prickett, PhDNational Cancer Institute/National Institutes of Health
3:50 – 4:05 p.m. A Bispecific Chimeric Antigen Receptor Molecule Enhances T Cell Activation Through Dual Immunological Synapse Formation and Offsets Antigen Escape in Glioblastoma  PDF  VIDEO
Nabil Ahmed, MD – Baylor College of Medicine
4:05 – 4:20 p.m. Panel Discussion
4:20 – 4:50 p.m. Break
   

Concurrent Session: Immunogenomics and Oncogenetics

1.5 AMA PRA Category 1 Credits™

Co-Chairs:
Francesco M. Marincola, MD – Sidra Medical and Research Center
Kai Wucherpfennig, MD, PhD – Harvard Medical School
4:50 – 4:55 p.m. Introduction
Francesco M. Marincola, MD – Sidra Medical and Research Center
4:55 – 5:10 p.m. Discovery and Characterization of an Immunogenic Neoantigen in a Patient with Metastatic Triple Negative Breast Cancer
Yasmine Assadipour, MD – National Insitutes of Health
5:10 – 5:25 p.m. In Vivo Discovery of Novel Targets for Cancer Immunotherapy
Kai Wucherpfennig, MD, PhD – Harvard Medical School
5:25 – 5:40 p.m. Understanding the CD8T Cell Response to Melanoma Using Transnuclear Mouse Models  PDF  VIDEO
Stephanie Dougan, PhD – Dana-Farber Cancer Institute
5:40 – 5:55 p.m. Toward the Identification of Genetic Determinants of Cancer Immune Responsiveness           
Davide Bedognetti, MD, PhD – Sidra Medical and Research Center
5:55 – 6:10 p.m. From Immunogenetic Polymorphism to Functional Antitumor Lymphocyte Mitochondrial Dynamics  PDF
Anil Shanker, PhD – Meharry Medical College School of Medicine/Vanderbilt-Ingram Cancer Center
6:10 – 6:15 p.m. Closing
Kai W. Wucherpfenning, MD, PhD – Harvard Medical School
     

Concurrent Session: Cutting-Edge Clinical Trials

1.5 AMA PRA Category 1 Credits™

Co-Chairs:
Sandra Demaria, MD – New York University School of Medicine
Elizabeth M. Jaffee, MD – Johns Hopkins University
4:50 – 4:55 p.m. Introduction
Sandra Demaria, MD – Weill Cornell Medical College
4:55 – 5:15 p.m. PD1 Modulation in Mismatch Repair Deficient Tumors
Dung T. Le, MD – The Sidney Kimmel Comprehensive Cancer Center at John Hopkins University
5:15 – 5:35 p.m. Targetable Immune Escape Mechanisms in Hodkins' Lymphoma
Margaret A. Shipp, MD – Dana-Farber Cancer Institute
5:35 – 5:55 p.m. Radiotherapy as Adjuvant to Immunotherapy: Clincal Translation  PDF  VIDEO
Silvia Formenti, MD – New York Presbyterian/Weill Cornell Medical Center
5:55 – 6:10 p.m. Autologous HER2 CMV Bispecific CAR T Cells are Safe and Demonstrate Clincal Benefit for Glioblastoma in a Phase I Trial  PDF  VIDEO
Nabil Ahmed, MD – Baylor College of Medicine
6:10 – 6:15 p.m. Closing
Elizabeth M. Jaffee, MD – The Sidney Kimmel Comprehensive Cancer Center at John Hopkins University
 

Saturday, November 7, 2015

Cancer Immunotherapy Trials Network Update

.75 AMA PRA Category 1 Credits™

7:45 – 8:35 a.m. Martin Cheever, MD – Fred Hutchinson Cancer Research Center
 

Coinhibition & Costimulation

1.75 AMA PRA Category 1 Credits™

Co-Chairs:
Andrew D. Weinberg, PhD – Earle A. Chiles Research Institute, Providence Medical Center
Jedd D. Wolchok, MD, PhD – Memorial Sloan Kettering Cancer Center
8:35 – 8:40 a.m. Introduction  PDF  VIDEO
Andrew D. Weinberg, PhD – Earle A. Chiles Research Institute, Providence Medical Center
8:40 – 9:05 a.m. Combined Coinhibition in the Clinic  PDF  VIDEO
Jedd D. Wolchok, MD, PhD – Memorial Sloan Kettering Cancer Center
9:05 – 9:30 a.m. Preclinical/Costimulation within Tumor Immunotherapy  PDF  VIDEO
Isabelle Le Mercier, PhD – Geisel School of Medicine at Dartmouth
9:30 – 9:50 a.m. OX40 Agonist Agents in Pre-clinical Models  PDF  VIDEO
Daniel Hirschhorn-Cymerman, PhD – Memorial Sloan Kettering Cancer Center
9:50 – 10:05 a.m. Agonist Anti-4-1 BB Plus Neutralizing Anti-CTLA-4 or –PD-L1 Synergize to Promote Tumor Regression by Rescuing Dying Dysfunctional CD8+ T Cells Within the Tumor Microenvironment
Brendan Horton, MD, PhD – University of Chicago
10:05 – 10:20 a.m. PD-1 Blockade Upregulate Tim-3 Expression as a Compensatory Regulation of Immune Check Point Receptors in HNSCC TIL  PDF
Gulidana Shayan – University of Pittsburgh
10:20 – 10:35 a.m. Break
 

Mechanisms and Responses to Immune Therapy

1.5 AMA PRA Category 1 Credits™

Co-Chairs:
Thomas F. Gajewski, MD, PhD – University of Chicago
Jennifer A. Wargo, MD, MMSc  – University of Texas MD Anderson Cancer Center
10:35 – 10:40 a.m. Introduction
Thomas Gajewski, MD, PhD – University of Chicago
10:40 – 11 a.m. Antigen Identification from Patients Responding to Immunotherapy
Paul F. Robbins, PhD – National Cancer Institute/National Institutes of Health
11 – 11:20 a.m. Understanding Responses to Therapy: the Tissue is the Issue  VIDEO
Jennifer A. Wargo, MD, MMSc – University of Texas MD Anderson Cancer Center
11:20 – 11:40 a.m. Molecular Determinants of the Host Immune Response to Cancer
Thomas F. Gajewski, MD, PhD – University of Chicago
11:40 – 11:55 a.m. Characterization of Oncogenic Pathways Linked with T Cell Exclusion in Urothelial Bladder Cancer
Randy Sweis, MD – University of Chicago
11:55 – Noon Closing
Jennifer A. Wargo, MD, MMSc – University of Texas MD Anderson Cancer Center
 

Late Breaking Abstract Session II

Non-CME Session
Noon – 12:15 p.m. Interim Results of an Ongoing Phase I, Dose Escalation Study of MGA271 (Fc-Optimized Humanized Anti-B7-H3 Monoclonal Antibody) in Patients with Refractory B7-H-3-Expressing Neoplasms or Neoplasms whose Vasculature Expresses B7-H3  PDF
John D. Powderly II, MD, CD1 – Carolina BioOncology Institute, PLLC
12:15 – 12:30 p.m. Treatment of Leukemia Antigen-Loss Relapses Occurring after CD19-targeted Immunotherapies by Combination of Anti-CD123 and Anti-CD19 Chimeric Antigen Receptor T Cells   
Marco Ruella, MD – University of Pennsylvania
12:30 – 12:45 p.m. Efficacy of Anti-ICOS Agonist Monoclonal Antibodies in Preclinical Tumor Models Provides a Rationale for Clinical Development as Cancer Immunotherapeutics  PDF
Michael J. Briskin, PhD – Jounce Therapeutics
12:45 – 2 p.m. Lunch and Poster Viewing
 

Presidential Session

1.0 AMA PRA Category 1 Credits™

Chair
Howard L. Kaufman, MD, FACS – Rutgers Cancer Institute of New Jersey
2 – 2:05 p.m. Introduction
Howard L. Kaufman, MD, FACS – Rutgers Cancer Institute of New Jersey
2:05 – 2:20 p.m. Inhibition of the T-Cell Oxygen Sensing Machinery Promotes Anti-Tumor Efficacy  PDF
David Clever – National Cancer Institute/National Institute of Health – Surgery Branch
2:20 – 2:35 p.m. Selection of Circulating PD-1 + Lymphocytes from Cancer Patients Enriches for Tumor-Reactive and Mutation- Specific Lymphocytes
Alena Gros, PhD – National Cancer Institute/National Institute of Health – Surgery Branch
2:35 – 2:50 p.m. Virus-Specific CD8+ T Cells Infiltrate Melanoma Lesions and Retain Function Despite High PD-1 Expression  PDF
Dan Erkes – Thomas Jefferson University
2:50 – 3:05 p.m. Inhibition of Fatty Acid Oxidation Modulates Immunosuppressive Functions of Myeloid-Derived Suppressor Cells and Enhances Cancer Therapies  PDF
Amir Al-Khami, PhD – Louisiana State University Health Sciences Center
 

SITC Immunoscore Validation Project Update

.25 AMA PRA Category 1 Credits™

3:05 – 3:20 p.m. SITC Immunoscore Validation Project Update
Bernard Fox, PhD – Earle A. Chiles Research Institute, Providence Cancer Center
 

SITC Biomarkers Task Force Update

.25 AMA PRA Category 1 Credits™

3:20 – 3:35 p.m. SITC Biomarkers Task Force Update  PDF
Lisa H. Butterfield, PhD – University of Pittsburgh
3:35 – 4:05 p.m. Break
 

Concurrent Session: Precision Immunology

1.5 AMA PRA Category 1 Credits™

Co-Chairs:
Holden T. Maecker, PhD – Stanford University Medical Center
Drew M. Pardoll, MD, PhD – Johns Hopkins University School of Medicine
4:05 – 4:10 p.m. Introduction  PDF
Holden T. Maecker, PhD – Stanford Univeristy 
4:10 – 4:35 p.m. Pre-existing Immunity and Treatment Outcome with Anti-PD1 Therapy in Melanoma  PDF  VIDEO
Paul Tumeh, MD – University of California Los Angeles
4:35 – 4:55 p.m. Epitope Signatures and Melanoma Response to CTLA4 Therapy
Timothy Chan, MD, PhD – Memorial Sloan Kettering Cancer Center
4:55 – 5:15 p.m. PD-1 Blockade in Mismatch Repair Deficient Tumors  PDF  VIDEO
Luis A. Diaz, MD – Johns Hopkins Sidney Kimmel Cancer Center
5:15 – 5:30 p.m. Dissecting the Tumor Micro-Environment in Triple Negative Breast Cancer Identifies a Mutually Exclusive Expression Pattern of the Immune Co-Inhibitory Molecules B7-H4 and PD-L1
Kurt Schalper, MD, PhD – Yale University
 

Concurrent Session: Innate Immunity

1.5 AMA PRA Category 1 Credits™

Co-Chairs:
Vincenzo Bronte, MD – University of Verona
Keith L. Knutson, PhD – Mayo Clinic Jacksonville
4:05 – 4:10 p.m. Introduction
Keith L. Knutson, PhD – Mayo Clinic Jacksonville
4:10 – 4:35 p.m. PTX3 as an Extrinsic Oncosuppressor Regulating Complement and Macrophage Driven Inflammation  PDF  VIDEO
Mantovani Alberto, MD – Humanitas University
4:35 – 5 p.m. Chimeric Endocrine Receptor-Expressing T cells Influenced by the Microbiodata Delay Ovarian Cancer Progression by Boosting Pre-Existing Anti-Tumor Immunity  PDF  VIDEO
Jose R. Conejo-Garcia, MD, PhD – The Wistar Institute
5 – 5:15 p.m. Targeting KIT on Innate Immune Cells Enhances the Antitumor Activity of Checkpoint Inhibitors in Vivo
Joseph McLaughlin, MD – Yale New Haven Hospital Smilow Cancer Center
5:15 – 5:30 p.m. Local Immunotherapy with ONCOS-102 Shapes Harmful Tumor Associated CD68+ Macrophages to Become Beneficial Cells that Correlate with Increased Overall Survival  PDF  VIDEO
Dmitriy Zamarin, MD, PhD – Memorial Sloan Kettering Cancer Center
 

Sunday, November 8, 2015

Hot Topic Session on the Value of Cancer Immunotherapy

Non-CME Session
Chair:

Howard L. Kaufmann, MD, FACS – Rutgers Cancer Institue of New Jersey

7:45 – 7:50 a.m. Welcome and Introductions
Howard L. Kaufman, MD, FACS – Rutgers Cancer Institute of New Jersey 
7:50 – 8 a.m. Perspective Biomarkers  PDF  VIDEO
Lisa H. Butterfield, PhD – University of Pittsburgh
8 – 8:15 a.m. Value: "Real World" Points  PDF  VIDEO
William McGivney, PhD
8:15 – 8:20 a.m. Perspective: Analytics/Immunotherapy  VIDEO
Kimberly A Shafer-Weaver, PhD – AstraZeneca
8:20 – 8:25 a.m. Perspective: Industry  VIDEO
Kevin Trapp – Bristol-Myers Squibb
8:25 – 8:30 a.m. Perspective: Patient Support  PDF  VIDEO
Gwen Darien – Cancer Support Community
8:30 – 8:35 a.m. Panel Discussion
8:35 – 9:15 a.m. Audience Questions & Answer
Moderator: Peter P. Yu, MD, FACP, FASCO – Palo Alto Medical Foundation

 

2015 Annual Meeting 2015 Annual Meeting 2015 Annual Meeting 2015 Annual Meeting 2015 Annual Meeting

Save the Date!

Save the dates for SITC 2016!
November 9 – 13, 2016
Gaylord National Hotel & Convention Center, National Harbor, Maryland

Thank You, Supporters!

Thank you, SITC 2015 supporters. Because of your generosity, SITC 2015 was a great success!

Interested in supporting other SITC programs? Confirm your support today!

Connect with SITC!

SITC: Join Today

SITC: TWITTERSITC: LINKEDINSITC: YOUTUBESITC: ONCOLOGY TUBE